A study published in the Records of Natural Products investigated the antifungal properties of volatile compounds extracted from high-potency Cannabis sativa. The research focused on their effects against Cryptococcus neoformans, a fungus responsible for severe infections, especially in immunocompromised individuals. The study found that α-humulene, one of the isolated compounds, demonstrated potent antifungal activity with an IC₅₀ value of 1.18 µg/mL and a minimum inhibitory concentration (MIC) of 5.0 µg/mL. In contrast, β-caryophyllene showed weaker activity, and caryophyllene oxide was inactive against C. neoformans.
Further research has explored the antifungal potential of synthetic cannabinoids. A study published in Antimicrobial Agents and Chemotherapy examined abnormal cannabinoids (AbnCBDs) and their effects on various Candida species. The findings indicated that certain AbnCBD derivatives, particularly compound 3, significantly inhibited the growth of Candida albicans, including fluconazole-resistant strains. Additionally, compound 3 disrupted biofilm formation and eradicated mature biofilms in C. albicans, suggesting its potential as a therapeutic agent.
The antimicrobial properties of Cannabis sativa resins have also been studied. Research indicates that these resins can inhibit the growth of several pathogenic fungi, including Candida albicans, Aspergillus fumigatus, and Trichophyton mentagrophytes. The antifungal activity is attributed to the complex profile of terpenes present in the resins, rather than the major cannabinoids like THC or CBD .
These studies highlight the potential of cannabis-derived compounds as antifungal agents. However, further research, including clinical trials, is necessary to fully understand their efficacy and safety profiles before they can be considered for therapeutic use.
Dabbin-Dad Newroom
If you liked this post, say thanks by sharing it
